Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer
Open Access
- 15 July 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (14) , 4036-4044
Abstract
Platinum-based chemotherapy constitutes the backbone of clinical care in advanced solid cancers such as high-grade serous ovarian cancer (HGSOC) and has prolonged survival of millions of patients with cancer. Most of these patients, however, become resistant to chemotherapy, which generally leads to a fatal refractory disease. We present a comprehensive stochastic mathematical model and simulator approach to describe platinum resistance and standard-of-care (SOC) therapy in HGSOC. We used pre- and posttreatment clinical data, including 18F-FDG-PET/CT images, to reliably estimate the model parameters and simulate “virtual patients with HGSOC.” Treatment responses of the virtual patients generated by our mathematical model were indistinguishable from real-life patients with HGSOC. We demonstrated the utility of our approach by evaluating the survival benefit of combination therapies that contain up to six drugs targeting platinum resistance mechanisms. Several resistance mechanisms were already active at diagnosis, but combining SOC with a drug that targets the most dominant resistance subpopulation resulted in a significant survival benefit. This work provides a theoretical basis for a cancer treatment paradigm in which maximizing platinum's killing effect on cancer cells requires overcoming resistance mechanisms with targeted drugs. This freely available mathematical model and simulation framework enable rapid and rigorous evaluation of the benefit of a targeted drug or combination therapy in virtual patients before clinical trials, which facilitates translating preclinical findings into clinical practice. Significance: These findings present a comprehensive mathematical model for platinum resistance and standard-of-care therapy in a solid cancer, allowing virtual evaluation of novel therapy regimens. Cancer Res; 78(14); 4036–44. ©2018 AACR.Keywords
All Related Versions
Funding Information
- Research Council of Finland (292402)
This publication has 34 references indexed in Scilit:
- Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA-IVInternational Journal of Gynecological Cancer, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Clinical Trials in Recurrent Ovarian CancerInternational Journal of Gynecological Cancer, 2011
- Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinomaOncogene, 2010
- Review: Practical considerations in ovarian cancer chemotherapyTherapeutic Advances in Medical Oncology, 2010
- Peritoneal carcinosis of ovarian originWorld Journal of Gastrointestinal Oncology, 2010
- The Preclinical Natural History of Serous Ovarian Cancer: Defining the Target for Early DetectionPLOS Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Integrated mechanistic and data-driven modelling for multivariate analysis of signalling pathwaysJournal of The Royal Society Interface, 2006